Core Viewpoint - The company has successfully completed the review period for the new drug clinical trial application for CBT-199, a potential best-in-class ophthalmic candidate, and is authorized to proceed with Phase 2 clinical trials [1][2]. Group 1: Clinical Trial Progress - The company's wholly-owned subsidiary, ADS Therapeutics LLC, registered in Delaware, USA, has had its clinical trial application for CBT-199 accepted by the FDA without any suspension orders [1]. - CBT-199 is a novel topical ophthalmic emulsion designed to treat presbyopia, a common age-related condition that affects the ability to focus on near objects [1]. - The clinical trial for CBT-199 is now recognized as safe to advance, marking a significant milestone in its clinical development [2]. Group 2: Product Details - CBT-199 utilizes the company's proprietary non-aqueous platform formulation, which includes a parasympathomimetic miotic agent to induce pupil constriction, thereby improving near vision through a pinhole effect [1]. - The formulation is designed to prevent the degradation of active ingredients over time, enhancing drug stability, and features a consumer-friendly multi-dose bottle design for prolonged shelf life and a comfortable medication experience [1]. Group 3: Future Developments - The drug discovery process for CBT-199 commenced in China in 2023, with preclinical animal studies evaluating safety and tolerability starting in June 2023 [2]. - The company will continue to monitor the review progress closely and will provide updates to shareholders and potential investors regarding the latest developments in its business [2].
拨康视云-B(02592)：CBT-199新药临床试验申请已生效，临床试验被认定为可安全推进